14 completed, 13 unknown, 7 not yet recruiting, 5 recruiting. 29 Phase 2, 13 Phase 1, 11 Phase 3, 1 Not applicable, 1 Phase 4.
Follow Extensive-Stage Small Cell Lung Cancer: new trials by email Literature Review of Extensive-Stage Small Cell Lung Cancer trials Research Report on Extensive-Stage Small Cell Lung Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer ZL-1310 in combination with Atezolizumab or Durvalumab, Carboplatin/Etoposide in Combination with Atezolizumab followed by maintenance Atezolizumab with Lurbinectedin, Carboplatin/Etoposide or Cistplatin/Etoposide in Combination with Durvalumab induction followed by Durvalumab maintenance - Extensive-Stage Small Cell Lung Cancer | Phase 3 | Not yet recruiting | Zai Lab (Shanghai) Co., Ltd. | 530 | 2026-12-31 | 2026-08-31 |
| Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease Autologous B7-H3 CAR T, Cyclophosphamide, Fludarabine - Recurrent Small Cell Lung Cancer, Extensive-Stage Small Cell Lung Cancer | Phase 1 | Recruiting | National Cancer Institute (NCI) | 40 | 2026-10-16 | 2026-10-21 |
| A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer QLC5508, QL2107, Tislelizumab - Extensive-stage Small Cell Lung Cancer | Phase 3 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 556 | 2026-10-15 | 2026-09-03 |
| Real-World Use of Tarlatamab in Chinese Patients With Small-Cell Lung Cancer Tarlatamab - Extensive-Stage Small Cell Lung Cancer | Active not recruiting | Ruijin Hospital | 26 | 2026-08-03 | 2026-10-21 | |
| A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC) Tislelizumab - Advanced Non-Small Cell Lung Cancer, Extensive-Stage Small Cell Lung Cancer | Recruiting | BeOne Medicines | 440 | 2026-06-05 | 2026-10-15 | |
| Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer Tarlatamab, Sacituzumab Govitecan - Extensive-Stage Small Cell Lung Cancer, Extrapulmonary Neuroendocrine Carcinoma | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2026-04-25 | 2026-04-28 | |
| Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC Sacituzumab Tirumotecan, Anlotinib - Extensive-Stage Small Cell Lung Cancer | Phase 2 | Not yet recruiting | China Medical University, China | 30 | 2026-02-24 | 2026-02-05 |
| Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer Benmelstobart, Anlotinib, Carboplatin or cisplatin - Extensive-stage Small Cell Lung Cancer | Phase 4 | Not yet recruiting | Peking Union Medical College Hospital | 50 | 2025-04-15 | 2025-04-23 |
| Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors ECI830, ribociclib, fulvestrant - Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors | Phase 1 / Phase 2 | Recruiting | Novartis Pharmaceuticals | 280 | 2025-04-03 | 2026-08-27 |
| A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). BMS-986489 (Atigotatug+Nivolumab), Atezolizumab, Carboplatin - Extensive-Stage Small Cell Lung Cancer | Phase 3 | Recruiting | Bristol-Myers Squibb | 530 | 2025-02-25 | 2026-10-13 |
| A Study of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequential Treatment for Extensive-stage Small Cell Lung Cancer Adebrelimab +Etoposide+Platinum-based drugs, Maintenance treatment period: - Extensive-Stage Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Fujian Cancer Hospital | 43 | 2025-02-01 | 2024-09-26 |
| Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001) High-dose Hyperfractionated Simultaneous Integrated Boost Radiotherapy, atezolizumab or durvalumab - Extensive-stage Small Cell Lung Cancer | Phase 3 | Not yet recruiting | Anhui Shi, MD | 182 | 2024-12-16 | 2024-12-05 |
| Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC Serplulimab, Lurbinectedin, Carboplatin - Extensive-Stage Small Cell Lung Cancer | Phase 2 | Recruiting | Guangzhou Institute of Respiratory Disease | 30 | 2024-12-01 | 2026-06-08 |
| Efficacy and Safety of Serplulimab With Chemotherapy and Aspirin in Untreated Extensive-Stage Small Cell Lung Cancer Serplulimab，Platinum-based Chemotherapy，Aspirin - Extensive-Stage Small Cell Lung Cancer, Treatment-naïve for Systemic Therapy Targeting Extensive-Stage Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 43 | 2024-10-01 | 2024-08-15 |
| MDT-Based Nursing for Small Cell Lung Cancer During Chemo-Immunotherapy Multidisciplinary Team-Based Nursing Intervention, Routine Nursing Care - Small Cell Lung Cancer, Extensive-Stage Small Cell Lung Cancer | Not applicable | Completed | Shanxi Province Cancer Hospital | 200 | 2024-07-01 | 2026-03-30 |
| Radiotherapy to All Residual Lesions After Chemoimmunotherapy Radiotherapy to all residual lesions, Chemoimmunotherapy - Extensive-stage Small Cell Lung Cancer | Phase 1 / Phase 2 | Unknown | Anhui Provincial Hospital | 150 | 2024-06-01 | 2024-08-09 |
| Study of Selinexor Combined With Olaparib in Relapsed/Refractory Extensive Stage Small Cell Lung Cancer Selinexor，Olaparib - Extensive-stage Small Cell Lung Cancer | Phase 1 / Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 49 | 2023-09-01 | 2023-08-04 |
| Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer Surufatinib, Anti-PD-1/L1 - Extensive-Stage Small Cell Lung Cancer | Phase 2 | Completed | Hutchison Medipharma Limited | 21 | 2022-09-27 | 2025-08-29 |
| Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer Neoantigen DNA vaccine, Durvalumab, TDS-IM v2.0 Device - Extensive-stage Small Cell Lung Cancer | Phase 2 | Active not recruiting | Washington University School of Medicine | 6 | 2022-03-30 | 2025-10-22 |
| Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer Durvalumab, Cisplatin, Carboplatin - Extensive-stage Small Cell Lung Cancer | Phase 3 | Completed | AstraZeneca | 152 | 2021-11-11 | 2025-05-23 |
Showing 20 of 49. Sign in to see all of them.
Small Cell Lung Carcinoma (49) · Lung Neoplasms (3) · Breast Neoplasms (1) · Carcinoma, Neuroendocrine (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Small Cell (1) · Cytokine Release Syndrome (1) · Neoplasm Metastasis (1) · Pleural Effusion, Malignant (1) · Treatment Adherence and Compliance (1)
Bronchial Neoplasms (49) · Carcinoma, Bronchogenic (49) · Lung Diseases (49) · Neoplasms (49) · Neoplasms by Site (49) · Respiratory Tract Diseases (49) · Respiratory Tract Neoplasms (49) · Thoracic Neoplasms (49) · Lung Neoplasms (46) · Carcinoma (2) · Neoplasms by Histologic Type (2) · Neoplasms, Glandular and Epithelial (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Adenocarcinoma (1)
Etoposide (17) · Carboplatin (16) · Cisplatin (8) · atezolizumab (6) · durvalumab (5) · Radiotherapy (4) · anlotinib (3) · EC regimen (2) · Nivolumab (2) · PM 01183 (2) · guadecitabine (2) · obatoclax (2) · tislelizumab (2) · Albumin-Bound Paclitaxel (1) · Antineoplastic Agents (1)
Bristol-Myers Squibb (2) · Chinese Academy of Medical Sciences (2) · National Cancer Institute (NCI) (2) · Peking Union Medical College Hospital (2) · Washington University School of Medicine (2) · Zai Lab (Shanghai) Co., Ltd. (2) · Alaunos Therapeutics (1) · Anhui Provincial Hospital (1) · Anhui Shi, MD (1) · AstraZeneca (1) · BeOne Medicines (1) · BioNTech SE (1) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (1) · Catherine Shu (1) · Cephalon (1)
China (21) · United States (16) · Canada (6) · Spain (6) · Germany (5) · Italy (5) · United Kingdom (5) · Australia (4) · Czechia (4) · Poland (4) · France (3) · Japan (3) · Romania (3) · Belgium (2) · Bulgaria (2)
Anish Thomas, M.D. (1) · Bradford A. Perez, M.D. (1) · Catherine Shu, MD (1) · Daniel Morgensztern, MD (1) · David R Spigel, M.D. (1) · Dong Qian, M.D (1) · Dong Wang, PH.D (1) · Gregory Kalemkerian, MD (1) · Jean Viallet, MD (1) · Jeffrey Ward, M.D., Ph.D. (1) · JinMing Yu, PhD (1) · Junling Li, doctor (1)
PMID 17008692, PMID 21296855, PMID 21512407, PMID 24997137, PMID 33002543, PMID 33493586, PMID 35576956, PMID 36275912, PMID 37350968, PMID 38582540, PMID 39252865, PMID 42498486
2019 (1)